drugset / Trial / NCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Timeline
- Start
- 2025-11-24
- Primary completion
- 2026-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Comparator | Alomnertinib | Unknown | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Comparator | Furmonertini | Unknown | — | — |
| Comparator | Osimertinib | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |